表紙
市場調查報告書

藥物濫用抑制劑、治療藥市場:技術、競爭、R&D形勢的評估

Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H2 2018

出版商 GervanoRA Data Services LLP 商品編碼 769579
出版日期 內容資訊 英文 186 Pages
訂單完成後即時交付
價格
藥物濫用抑制劑、治療藥市場:技術、競爭、R&D形勢的評估 Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H2 2018
出版日期: 2019年01月20日內容資訊: 英文 186 Pages
簡介

本報告提供全球藥物濫用抑制劑、治療藥市場相關調查,未滿足需求與機會,市場動態,開發平台藥物的認證計劃預測,臨床實驗摘要,競爭情形,及主要企業的簡介等系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 藥物中毒 (可卡因 & 甲基苯丙胺) 市場概要

  • 藥物中毒概要
  • 藥物中毒全世界的情形
  • 藥物中毒的流行病學
  • 流行病學預測
  • 藥物中毒的建議治療方法

第4章 藥物濫用概要

  • 藥物濫用與抑制劑
  • 藥物濫用的影響要素
  • 藥物濫用的影響、症狀
  • 藥物濫用的目前治療方法
  • 藥物濫用:健康、社會、經濟的影響

第5章 濫用抑制劑的契約概要

  • 契約 (合併/收購/合作)

第6章 藥物濫用抑制劑:近幾年的開發、技術

  • 藥物濫用抑制劑的配合策略
  • 藥物濫用抑制劑的配合技術
  • 濫用藥物的國際指南
  • 藥物濫用的治療的未滿足醫療需求、差距
  • 藥物濫用的全球趨勢、規定的發展
  • 藥物濫用抑制劑配合的限制

第7章 可卡因 & 甲基苯丙胺藥物濫用抑制劑的開發平台分析

  • 開發中的治療藥:各開發階段
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各企業、大學、機關

第8章 藥物濫用抑制劑:的開發平台分析

  • 開發平台分析:各開發階段
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各類藥物
  • 開發平台分析:各作用機制
  • 開發平台分析:各企業、大學、機關

第9章 醫藥品核准計劃的預測

  • 調查手法
  • 藥物濫用抑制劑的銷售分析
  • 可卡因 & 甲基苯丙胺藥物濫用抑制劑的銷售分析

第10章 臨床實驗摘要

  • 可卡因 & 甲基苯丙胺藥物濫用抑制劑
  • 藥物濫用抑制劑
  • 中止的計劃

第11章 現在、未來的競爭情形

  • 新興企業
  • 新興企業的簡介
  • 大學、機關

第12章 用語

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GERPH226

GervanoRA's pipeline analysis and opportunity assessment report "Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H2 2018" analyzed and assessed Stimulant Addiction (Cocaine and Methamphetamine) Market Overview by considering the global scenarios, epidemiology and proposed treatments for the Stimulant Addiction. The report also provides information related to Stimulant Abuse and Deterrence, factors affecting, treatments and impact on Health, Social and Economy through Stimulant Abuse. The Report also focuses on the global trends, recent developments and technologies like the formulation strategies and formulation technologies.For a good understanding about the report we have provided the Pipeline Analysis for Cocaine and Methamphetamine Drug Abuse Deterrent and Stimulant Drug Abuse Deterrent. We have in turn segmented the Chapter with respect to the Highest Stage of development, Geography, Route of Administration, Drug Class and Mechanism of Action.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORTS MAJOR FINDINGS
  • 2.2. KEY PIPELINE EVENTS 2018 TO 2034

3. STIMULANT ADDICTION (COCAINE & METHAMPHETAMINE) MARKET OVERVIEW

  • 3.1. STIMULANT ADDICTION OVERVIEW
  • 3.2. STIMULANT ADDICTION GLOBAL SCENARIOS
  • 3.3. STIMULANT ADDICTION EPIDEMIOLOGY
  • 3.4. EPIDEMIOLOGY FORECAST
    • 3.4.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.4.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
  • 3.5. STIMULANT ADDICTION PROPOSED TREATMENTS

4. STIMULANT ABUSE OVERVIEW

  • 4.1. STIMULANT ABUSE AND DETERRENCE
  • 4.2. FACTORS AFFECTING ON STIMULANT ABUSE
  • 4.3. EFFECTS AND SYMPTOMS OF STIMULANT ABUSE
  • 4.4. CURRENT TREATMENTS OF STIMULANT ABUSE
  • 4.5. STIMULANT ABUSE - IMPACT ON HEALTH, SOCIAL AND ECONOMY

5. ABUSE DETERRENT DEALS OVERVIEW

  • 5.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    • 5.1.1. COLLABORATION AGREEMENTS
    • 5.1.2. LICENSING AGREEMENTS
    • 5.1.3. TERMINATION AGREEMENTS AND SETTLEMENTS
    • 5.1.4. FUNDING & CONTRACTS
    • 5.1.5. PARTNERSHIPS
    • 5.1.6. ACQUISITIONS

6. STIMULANT ABUSE DETERRENTS-RECENT DEVELOPMENTS AND TECHNOLOGIES

  • 6.1. STIMULANT ABUSE DETERRENT FORMULATION STRATEGIES
  • 6.2. STIMULANT ABUSE DETERRENT FORMULATION TECHNOLOGIES
  • 6.3. INTERNATIONAL GUIDELINES FOR ABUSABLE SUBSTANCES
  • 6.4. UNMET MEDICAL NEEDS AND GAPS IN THE TREATMENT OF STIMULANT ABUSE
  • 6.5. STIMULANT ABUSE GLOBAL TRENDS AND REGULATORY DEVELOPMENTS
  • 6.6. LIMITATIONS OF STIMULANT ABUSE DETERRENT FORMULATIONS

7. PIPELINE ANALYSIS OF COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT

  • 7.1. THERAPEUTICS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT
    • 7.1.1. PHASE II MOLECULES
    • 7.1.2. PHASE I MOLECULES
    • 7.1.3. PRECLINICAL MOLECULES
    • 7.1.4. EARLY R&D MOLECULES
    • 7.1.5. INACTIVE MOLECULES
  • 7.2. PIPELINE ANALYSIS BY GEOGRAPHY
  • 7.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • 7.4. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

8. PIPELINE ANALYSIS OF STIMULANT DRUG ABUSE DETERRENT

  • 8.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 8.1.1. PRE-REGISTRATION (FILED) MOLECULES
    • 8.1.2. PHASE III MOLECULES
    • 8.1.3. PHASE II MOLECULES
    • 8.1.4. PHASE I MOLECULES
    • 8.1.5. PRECLINICAL MOLECULES
    • 8.1.6. EARLY R&D (DISCOVERY) MOLECULES
  • 8.2. PIPELINE ANALYSIS BY GEOGRAPHY
  • 8.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • 8.4. PIPELINE ANALYSIS BY DRUG CLASS
  • 8.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
  • 8.6. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

9. ESTIMATED DRUG APPROVAL TIMELINES

  • 9.1. METHODOLOGY
  • 9.2. STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    • 9.2.1. UNITED STATES (FDA) ESTIMATIONS
    • 9.2.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS
  • 9.3. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    • 9.3.1. UNITED STATES (FDA) ESTIMATIONS
    • 9.3.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS

10. CLINICAL TRIAL SUMMARY

  • 10.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT
    • 10.1.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    • 10.1.2. ONGOING CLINICAL TRIALS SUMMARY
    • 10.1.3. PLANNED CLINICAL TRIAL SUMMARY
    • 10.1.4. RECENTLY COMPLETED CLINICAL TRIALS
  • 10.2. STIMULANT DRUG ABUSE DETERRENT
    • 10.2.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    • 10.2.2. PLANNED CLINICAL TRIAL SUMMARY
    • 10.2.3. RECENTLY COMPLETED TRIALS
  • 10.3. WITHDRAWN AND DISCONTINUED PROJECTS

11. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 11.1. EMERGING COMPANIES
  • 11.2. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS AND MILESTONES
    • 11.2.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EMERGING COMPANIES
    • 11.2.2. STIMULANT DRUG ABUSE DETERRENT EMERGING COMPANIES
  • 11.3. UNIVERSITIES AND INSTITUTES

12. ABBREVIATIONS

LIST OF TABLES

  • TABLE 1: METHAMPHETAMINE V/S COCAINE
  • TABLE 2: ILLICIT DRUG USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 3: STIMULANT USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 4: COCAINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 5: METHAMPHETAMINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
  • TABLE 6: COLLABORATION AGREEMENTS, 2000-2018
  • TABLE 7: LICENSING AGREEMENTS, 2013-2018
  • TABLE 8: TERMINATION AGREEMENTS
  • TABLE 9: FUNDING AND CONTRACTS
  • TABLE 10: PARTNERSHIPS DEALS
  • TABLE 11: ACQUISITION DEALS
  • TABLE 12: STAGE OF DEVELOPMENT V/S FORMULATION STRATEGIES
  • TABLE 13: MOLECULES BELONGING TO TYPE 3 FORMULATION STRATEGY
  • TABLE 14: MOLECULES BELONGING TO TYPE 2 FORMULATION STRATEGY
  • TABLE 15: MOLECULE BELONGING TO TYPE 1 FORMULATION STRATEGY
  • TABLE 16: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE II PIPELINE MOLECULES
  • TABLE 17: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE I PIPELINE MOLECULES
  • TABLE 18: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PRECLINICAL STAGE PIPELINE MOLECULES
  • TABLE 19: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EARLY R&D PIPELINE MOLECULES
  • TABLE 20: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT INACTIVE PIPELINE MOLECULES
  • TABLE 21: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • TABLE 22: PRE-REGISTRATION (FILED) MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 23: PHASE III MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 24: PHASE II MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 25: PHASE I MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 26: PRECLINICAL MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 27: EARLY R&D MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
  • TABLE 28: LIST OF COMPANIES WITH PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
  • TABLE 29: LIST OF UNIVERSITIES AND INSTITUTES WITH PIPELINE MOLECULES
  • TABLE 30: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
  • TABLE 31: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
  • TABLE 32: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
  • TABLE 33: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
  • TABLE 34: MN-166 (IBUDILAST) PHASE II CLINICAL TRIAL STUDY DESIGN
  • TABLE 35: SYN117 (NEPICASTAT) PHASE II CLINICAL TRIAL STUDY DESIGN
  • TABLE 36: MEASURED VALUE FOR PRIMARY MEASURE- ABSTINENCE
  • TABLE 37: MEASURED VALUE FOR SECONDARY MEASURE- REDUCTION IN USE
  • TABLE 38: ONGOING PHASE II CLINICAL TRIALS
  • TABLE 39: ORADUR-METHYLPHENIDATE ER PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 40: HLD200 PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 41: HLD200 SECOND PIVOTAL PHASE III CLINICAL TRIALS STUDY DESIGN
  • TABLE 42: HLD100 PHASE II TRIAL RESULTS
  • TABLE 43: RBP-8000 PHASE II CLINICAL TRIALS STUDY DESIGN
  • TABLE 44: LIST OF UNIVERSITIES AND INSTITUTES

LIST OF FIGURES

  • FIGURE 1: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2021-2023
  • FIGURE 2: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2024-2028
  • FIGURE 3: KEY PIPELINE EVENTS, STIMULANT DRUG ABUSE DETERRENT, 2018-2034
  • FIGURE 4: COCAINE USE TRENDS, US, 2002-2016
  • FIGURE 5: COCAINE USE TRENDS, CANADA, 2004-2009
  • FIGURE 6: RELATIVE COMPARISION IN PREVALENCE OF COCAINE AND METHAMPHETAMINE DRUG USE, 2009-2013
  • FIGURE 7: COMPARISION OF COCAINE USERS BY AGE GROUP, 2015-2016
  • FIGURE 8: COMPARISION OF METHAMPHETAMINE USERS BY AGE GROUP, 2015-2016
  • FIGURE 9: COCAINE USE, 2015-2016
  • FIGURE 10: ILLICIT DRUG USERS, US, 2010-2016
  • FIGURE 11: PREVALENCE OF COCAINE USE, AGE GROUP, CANADA, 2008-2015
  • FIGURE 12: ILLICIT DRUG USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 13: STIMULANT USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 14: COCAINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 15: METHAMPHETAMINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
  • FIGURE 16: PHARMACOLOGICAL TREATMENT OPTIONS FOR STIMULANT ADDICTION
  • FIGURE 17: DEAL ACTIVITY, CNS STIMULANTS AND OPIOIDS
  • FIGURE 18: STRATEGIES FOR STIMULANT ABUSE DETERRENT FORMULATION
  • FIGURE 19: ANNUAL PREVALENCE AND NUMBER OF ILLICIT DRUG USERS AT THE GLOBAL LEVEL, 2010
  • FIGURE 20: ILLICIT DRUG USE AT THE GLOBAL LEVEL, 2008
  • FIGURE 21: COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
  • FIGURE 22: DALY'S COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
  • FIGURE 23: ANNUAL PREVALENCE OF THE USE OF COCAINE AND METHAMPHETAMINE BY REGION AND GLOBALLY, 2015
  • FIGURE 24: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 25: STIMULANT DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT- COMPANIES
  • FIGURE 26: STIMULANT DRUG DETERRENT PIPELINE ANALYSIS BY GEOGRAPHY